I had no symptoms but a simple blood test led to me finding out I had prostate cancer
A man who displayed no symptoms of prostate cancer until a blood test showed he had elevated levels of prostate specific antigen in his blood has told men: “if something bothers you, bother your GP.”
Peter Crussell was 64 when he attended a prostate cancer screening event with the men’s health charity CHAPS.
He first became aware of prostate cancer when his maternal grandfather died from complications of the disease in 1989, aged 80, when the disease spread to his bones.
But because his father had never suffered from prostate cancer, Peter believed his own risk was low.
That changed when a PSA test showed an elevated result.
And now, speaking out as part of Urology Awareness Month, Peter is urging men to take advantage of blood tests, even if they think they aren’t at risk and have no symptoms.
Mr Crussell, from Cambridge, said: “I had no symptoms. I never had to get up in the night, I never had any trouble urinating so I thought I had nothing to worry about. I was wrong,” he said.
After attending the prostate cancer screening event organised with the support of the Masonic
Province of Cambridgeshire in July 2024, Peter was contacted and told that his blood results showed he had elevated levels of PSA and should make an appointment to see his GP.
“My GP initially considered the results to be normal for my age but I decided I would pursue the matter further, especially since two of my uncles were subsequently diagnosed with prostate cancer,” he said.
His warning comes as the Department of Health and Social Care has withdrawn guidance which explicitly stated men had an active right to request a PSA test, which can indicate whether a man might have the disease.
“I wasn’t going to just ignore the results and follow the advice that if something bothers you, you should bother your GP.”
“I was lucky in that I was able to go to a separate screening programme to get a test so when I made an appointment with my GP I was armed with the results and with the advice from CHAPS that it needed to be investigated further.”
Further investigations at Addenbrooke’s Hospital, including a scan and a biopsy, confirmed that Peter had prostate cancer.
“They said the words I was dreading to hear,” he said. “Mr Crussell, you have prostate cancer.”
But there was also good news. “They told me that thanks to my test and my persistence in pushing for further investigations with my GP it was caught early and before it had spread. This meant that it could be treated.”
Peter subsequently underwent hormone treatment followed by a course of radiotherapy in 2025.
“I have to say that the Urology and Oncology departments at Addenbrooke’s were absolutely brilliant. They were efficient, kind and communicative, and I couldn’t fault them.”
A year after completing his treatment, Peter was told that he was cancer free with his PSA level down to 0.21 and he puts the success of the treatment down to an early diagnosis
“Without having that PSA test, I would not have been diagnosed because I never had any symptoms,” he said.
New figures from the CHAPS Men’s Health Charity highlight the need for prostate cancer screening.
“At just one event at Ely Masonic Lodge on the 22nd July 2026, 70 men were tested. Eight of those, or 11.4 per cent, received an abnormal result and were advised to seek further medical attention,” says Prof Chris Booth, retired consultant urologist and founder of CHAPS.
“Of those eight, CHAPS estimates that 2, or 25 per cent, may ultimately be diagnosed with prostate cancer.
“But the fact that they can have these results before symptoms have appeared greatly contributes to better outcomes and a better quality of life if they do have cancer, since it is likely to be isolated in the prostate.
“Symptoms tend to occur when the cancer grows and spreads, which makes it more difficult to be successfully treated and needs more robust treatment to eliminate the cancer,” he added.
The screening programme also identified men who, although having a normal PSA result, were considered to be at higher or intermediate risk.
“We’ll monitor these men and they will be recalled for further testing,” Prof Booth explained.
“This early risk-based approach is intended to identify developing cancers at an early and potentially curable stage while avoiding unnecessary testing of men at lower risk.”